Abstract
BACKGROUND AND AIM: Aspirin and statins are often taken together in clinical practice. The impact of combined use of aspirin and statin (CAS) therapy on individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) or advanced liver fibrosis (LF) remains uncertain. This study is aimed at exploring their associations in US adults. METHODS: This cross-sectional study used data from the 2011 to 2018 National Health and Nutrition Examination Survey, and 5889 participants were included. MASLD is based on the 2023 international expert consensus definition. Advanced LF is defined based on three commonly-used noninvasive fibrosis scores. Furthermore, prescriptions of aspirin and statins were categorized into untreated, single, and CAS to assess their potential associations with MASLD or advanced LF. RESULTS: The CAS group consisted mostly of older (66 years), male (58.5%), non-Hispanic White (74.5%) individuals who were highly educated (58.0%), obese (45.7%), never smokers (43.8%), moderate drinkers (38.5%), and had hypertension (75.3%) and diabetes (39.9%). CAS was associated with a 49% higher risk of MASLD (OR: 1.49; 95% CI: 1.12-1.99) and a 40% higher risk of advanced LF (OR: 1.40; 95% CI: 1.02-1.92) after full adjustment. Notably, stratification and interaction analyses demonstrated that metabolic parameters such as overweight/obese, diabetes, and hypertriglyceridemia significantly influenced the association between CAS and MASLD or advanced LF. CONCLUSIONS: In summary, the study indicates a positive correlation between CAS and MASLD or advanced LF. Using CAS should be cautious to avoid the increased risk of the above diseases.